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Lung cancer is a leading cause of cancer death in many industrial-
ized countries, with a 5-year survival rate of 14% at best (Wingo 
et al, 1995). Non-small cell lung cancer (NSCLC) accounts for
approximately 75% of all lung cancer, and surgery offers the best
chance of cure and long-term survival if the tumour is confined to
the lung and is resectable. Unfortunately, the majority of patients
present with disease not amenable to surgery because it either is
locally advanced or has metastasized. For the approximately
25–30% of NSCLC patients who present with locally advanced
cancer (stage IIIA or IIIB), fractionated thoracic radiation therapy
has been the mainstay of treatment (Ihde et al, 1991). Despite such
treatment, however, the overall outcome is invariably poor, with
a median survival time that ranges from 9–13 months, while the
2- and 5-year survival rates are respectively 15–20% and 5–9% at
best (Roswit et al, 1968; Holsti et al, 1980; Petrovich et al, 1981;
Perez et al, 1982). Measures to improve the survival of these
patients have been the subject of intense clinical investigation
during the past two decades, with recent efforts being focused on
multimodal therapy (Friess et al, 1987; Mattson et al, 1988;
Dillman et al, 1990; Trovo et al, 1990; Le Chevalier et al, 1991;
Morton et al, 1991; Sause et al, 1992; Schaake-Koning, 1992;
Trovo et al, 1992; Sause et al, 1995; Jeremic et al, 1996).
Combined thoracic radiotherapy and chemotherapy for locally
advanced NSCLC is theoretically appealing because it addresses
the need to control the primary lesion while also attempting to
eradicate occult distant micrometastases. Although the optimal
sequencing of chemotherapy and radiotherapy is still unclear, most
trials have used sequential rather than concurrent therapy, largely
to avoid the anticipated greater toxicity with the latter approach.
Some anticancer drugs also act as radiation-sensitizing agents.
For example, cisplatin is known to be a radiosensitizer (Douple,
1988), and when given in combination with radiotherapy to
patients with inoperable NSCLC, it has been reported to improve
both survival and local disease control at the price of causing
substantial side-effects (Schaake-Koning, 1992).
Irinotecan is a derivative of camptothecin with a strong activity
against NSCLC (Negoro et al, 1991). A phase II study of
irinotecan for previously untreated NSCLC showed a high
response rate of 31.9% (95% CI, 20.2–43.6%) (Fukuoka et al,
1992). A recent study of the combination of irinotecan with
cisplatin showed a very promising response rate of 52% (95% CI,
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Summary A study was undertaken to determine the maximum tolerated dose, the dose-limiting toxicities, and the response rate of irinotecan
administered weekly with concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer. In a phase I/II
clinical trial, patients with histologically documented, surgically unresectable stage IIIA or IIIB non-small cell lung cancer (NSCLC) were
enrolled. Irinotecan was administered as a 90 min intravenous infusion once weekly for 6 weeks. The starting dose was 30 mg m–2 and dose
escalation was done in 15 mg m–2 increments. Dose-limiting toxicity was defined as grade 3 nonhaematologic toxicity (excluding nausea,
vomiting and alopecia) or grade 4 haematologic toxicity according to the WHO criteria. Radiation was delivered to the primary tumour and
regional lymph nodes (40 Gy), followed by a boost to the primary tumour (20 Gy). Twenty-seven patients were entered into this study at three
irinotecan dose levels (30, 45 and 60 mg m–2). Twenty-six eligible patients were evaluated for toxic effects and clinical outcome. Severe
oesophagitis, pneumonitis, and diarrhoea occurred at 45 and 60 mg m–2. Three of the five patients given 60 mg m–2 developed grade 3 or 4
oesophagitis and pneumonitis. In addition, one patient died of pneumonitis after completing therapy at 45 mg m–2 in the phase II study. The
objective response rate was 76.9% (95% CI, 53.0–88.9%). Oesophagitis, pneumonitis, and diarrhoea are the dose-limiting toxicities of weekly
irinotecan combined with thoracic irradiation. The maximum tolerated dose and the dose for the phase II study were 60 and 45 mg m–2 wk–1,
respectively. This combined therapy for locally advanced non-small cell lung cancer is promising and shows acceptable toxicity.
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39–64%) in previously untreated NSCLC patients with acceptable
toxicities (Masuda et al, 1998).
Irinotecan is a potent topoisomerase I inhibitor that has under-
gone extensive clinical evaluation (Andoh et al, 1987). This agent
is a prodrug with limited activity itself, which is converted by
carboxylesterases into a biologically active metabolite (SN38)
(Kawato et al, 1991). We showed that SN38 enhanced the
radiosensitivity of a lung cancer cell line in vitro (Okishio et al,
1996). In addition, Tamura et al demonstrated that irinotecan
combined with radiation significantly prolonged the survival time
when compared with irinotecan or radiation alone in a small cell
lung cancer xenograft model (Tamura et al, 1997).
Based on these reports of in vitro and in vivo radiation enhance-
ment by irinotecan, we initiated a phase I/II trial of this drug
combined with concurrent radiation therapy for locally advanced
NSCLC. The major goals of the present study were: to determine
the maximum tolerated dose of irinotecan administered as a
90 min weekly infusion along with daily thoracic radiation therapy
in patients with locally advanced NSCLC, to determine the toxici-
ties of combined irinotecan-radiation therapy, and to evaluate the
response rate and feasibility of this regimen.
PATIENTS AND METHODS
Patient selection
Patients with histologically documented, surgically unresectable
stage IIIA or IIIB NSCLC according to the criteria reported by
Mountain (1986) were enrolled in this study. However, patients
who had received previous chemotherapy or radiation therapy
were excluded. A complete history and physical examination were
performed in all patients. The nature and purpose of the study were
fully explained to each patient. All patients signed an informed
consent approved by the institutional review boards of Osaka City
General Hospital, Osaka City University, School of Medicine, or
Osaka Prefectural Habikino Hospital.
Patients were required to have measurable disease, an Eastern
Cooperative Oncology Group (ECOG) performance status ≤ 2, an
age ≤ 75 years, and no active concomitant malignancy. Patients
with malignant pleural effusion were excluded. Measurable
disease meant that the tumour was demonstrated by conventional
chest roentgenograms or computed tomography (CT) of the chest.
In addition, all patients underwent a routine staging evaluation that
consisted of standard radiologic studies (including CT of the
abdomen and brain) as well as bone scanning.
Eligibility requirements also included the following: white
blood cell (WBC) count ³ 4000 mm–3, platelet count ³ 100000
mm–3, haemoglobin ³ 9.5 g dl–1, serum bilirubin < 1.5 mg dl–1,
serum AST/ALT ≤ twice the upper limit of normal, serum creati-
nine less than the upper limit of normal, and arterial partial
pressure of oxygen (PaO2) ³ 70 mmHg. Patients with markedly
impaired pulmonary function (%VC < 70%, %TLC < 70% or
%DLco < 60%), and those with disease that required irradiation of
more than half of the hemithorax were excluded from this study.
Height, weight, performance status, and tumour stage were
recorded. Initial laboratory data obtained included a complete
blood count, differential WBC count, platelet count, total and
direct bilirubin, AST, ALT, alkaline phosphatase, total protein,
albumin, blood urea nitrogen (BUN), creatinine, uric acid, serum
electrolytes, calcium, phosphate, and PaO2.
Irinotecan dosage
Irinotecan was administered as a 90 min i.v. infusion once every
week for 6 weeks. It was given at the start of the week before radi-
ation therapy. Because the patients also received daily radiation
therapy, the starting dose of irinotecan was only 30 mg m–2. Three
patients with NSCLC who required radiation therapy to the
primary tumour site were entered at each dose level, and the dose
was escalated in increments of 15 mg m–2 for successive groups 
of three new patients until dose-limiting toxicity was observed.
Dose-limiting toxicity was defined as grade 3 or 4 nonhaemato-
logic toxicity excluding nausea, vomiting and alopecia or grade
4 haematologic toxicity according to the WHO toxicity criteria
(World Health Organization, 1979). If one instance of dose-
limiting nonhaematologic and/or haematologic toxicity was
observed among three patients, an additional three patients were
scheduled to be treated at the same dose level, and dose escalation
would continue if dose-limiting toxicity was observed in only one
or two out of six patients. When three instances of dose-limiting
toxicity were observed among six patients, the present dose
level was defined as the maximum tolerated dose (MTD). The
dose for the phase II portion of the study was set one level lower
than the MTD.
Radiation therapy
Radiation therapy was performed concurrently with weekly
irinotecan infusion for 6 weeks. The treatment volume consisted of
original and boost volumes irradiated sequentially. The original
volume included the primary disease site with a margin of 1.5 cm
and the ipsilateral hilum. The entire width of the mediastinum was
included, with a margin of 1.5 cm around the radiographically
visible area of involvement on pretreatment chest X-ray films and
CT scans. The ipsilateral supraclavicular fossa was treated from
the cricoid cartilage laterally to the midclavicular line. The
subcarinal lymph nodes were included to 5 cm below the carina.
The boost volume included the original tumour volume and all
lymph nodes greater than 2 cm in diameter visualized on CT scan
with a margin of 1.5 cm.
The radiation dose to the original volume was 40 Gy in 20
fractions of 2.0 Gy over a period of 4 weeks, while the dose to the
boost volume was 20 Gy in 10 fractions of 2.0 Gy over a period
of 2 weeks. The spinal cord dose was limited to 40 Gy. Figure 1
summarizes the treatment schedule used in this study.
Evaluation of response and toxicity
For the assessment of response and toxicity, the following tests
were done once a week during treatment: complete blood count,
AST, ALT, alkaline phosphatase, lactate dehydrogenase, bilirubin,
creatinine, BUN, serum electrolytes, urinalysis, PaO2, and chest
X-ray film.
1 8 15 22 29 36 43 Day
Irinotecan
Radiotherapy
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Figure 1 Schedule for concurrent chemoradiotherapy1464 K Takeda et al
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Response and toxicity were evaluated in accordance with WHO
criteria (World Health Organization, 1979), except that grading of
oesophageal toxicity due to radiation was done according to the
ECOG criteria (Oken et al, 1982).
The eligibility, assessability, and response of each patient were
determined by extramural review. The commissioned reviewer
was expert in this area. A complete response was defined as the
disappearance of all lesions for at least 4 weeks. A partial response
was defined as a > 50% decrease in the sum of the products of the
greatest perpendicular diameters of all measurable lesions for at
least 4 weeks, without the development of new lesions. If no
changes of the disease occurred during treatment, the patient was
considered to have stable disease. Progressive disease was defined
as a > 25% increase in the sum of the products of the perpendicular
diameters of all measurable lesions, or the appearance of new
lesions.
Differences in response rate between groups of patients were
compared using chi-square (c2) test. Survival was calculated on
the basis of the period from the start of treatment to death or the
last follow-up evaluation. Survival curves were drawn using the
Kaplan–Meier method (Kaplan et al, 1958). Differences in
survival estimates between groups of patients were evaluated
using the log-rank test (Peto et al, 1977). All P-values were two-
tailed.
RESULTS
Patients characteristics
Twenty-seven patients entered into this study through three dose
escalations, and one patient was found to be ineligible because of
metastatic disease. The main clinical characteristics of the 26
eligible patients are listed in Table 1. There were 20 male and six
female, with a median age of 63 years (range: 32–75 years).
Twenty-two patients (84.6%) had an ECOG performance status of
0 or 1. Each of four patients (15.4%) with more than 5% weight
loss within the last 3 months also had an ECOG performance
status of 2. Sixteen patients (61.5%) had squamous cell carcinoma,
eight (30.8%) had adenocarcinoma, and two (7.7%) had other
nonclassifiable types of NSCLC. One patient (3.8%) was in stage
IIIA and 25 (96.2%) had stage IIIB disease, including one patient
with recurrence after curative surgery.
Twelve of the 26 patients (46.2%) completed chemotherapy as
scheduled. The major reasons for not completing the scheduled
therapy were toxicity (10/14, 71.4%), cerebral infarction as an
accidental complication (2/14, 14.3%), disease progression (1/14,
7.1%), and patient refusal (1/14, 7.1%). Eighteen of 26 patients
(69.2%) completed radiation therapy according to the protocol,
four (15.4%) completed it with minor variations, and four (15.4%)
failed to complete it (two due to pulmonary toxicity and one each
due to disease progression and cerebral infarction).
Toxicity
Oesophagitis, pulmonary toxicity (pneumonitis), and diarrhoea
were the dose-limiting toxicities of combined irinotecan-radiation
therapy (Table 2). Grade 3 oesophagitis and diarrhoea occurred in
one patient each at the 45 mg m–2 dose level, but when three more
patients received irinotecan at 45 mg m–2, there were no further
severe toxicities. At the 60 mg m–2 level, grade 4 pneumonitis and
grade 3 oesophagitis occurred in one patient each and one more
patient developed grade 4 oesophagitis when treatment was
extended at this dose level. Since three out of five patients devel-
oped severe toxicity, the maximum tolerated dose of irinotecan
was scored as 60 mg m–2 weekly and the dose used for the phase II
study was 45 mg m–2 weekly.
Table 1 Patient characteristics
Characteristic n %
Enrolled 27
Assessable 26
Age (years)
Median 63
Range 32–75
Sex
Male 20 76.9
Female 6 23.1
Performance status (ECOG)
0 1 3.8
1 21 80.8
2 4 15.4
Weight loss within last 3 months
< 5% 22 84.6
³ 5% 4 15.4
Histology
Squamous cell carcinoma 16 61.5
Adenocarcinoma 8 30.8
Others 2 7.7
Stage
IIIA 1 3.8
IIIB 25 96.2
Table 2 Major nonhaematologic toxicity
Toxicity (WHO grade)
Dose Oesophagitis Pneumonitis Diarrhoea
(mg m–2) Patients
(n) 012340 1 2 3 4 0 1 23 4
Phase I 30 4 1 3 0 0 0 3 0 1 0 0 1 2 1 0 0
4 5 7 033106 1 0 0 0 4 0 21 0
6 0 5 021112 0 0 2 1 4 1 00 0
Phase II 45 10 3 4 3 0 0 4 1 4 0 1* 7 2 1 1 0
*Treatment-related deathIrinotecan and concurrent radiation for NSCLC 1465
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Ten patients were enrolled in the phase II study and two of them
developed severe toxicity (grade 4 pneumonitis and grade 3 diar-
rhoea). The patient who developed Grade 4 pneumonitis died, and
this was a treatment-related death. He completed chemoradiation
therapy according to schedule, but developed a high fever and
dyspnoea at the end of treatment. Chest X-ray films showed
bilateral interstitial infiltrates. Oxygen and steroid pulse therapy
were given, followed by intubation and mechanical ventilation,
but he failed to respond.
Other nonhaematologic toxicities included dermatitis and
nausea/vomiting. One patient developed grade 3 wet desquama-
tion due to an allergic reaction to irinotecan and/or radiation at the
30 mg m–2 dose level. Severe nausea or vomiting (grade 2 and 3)
due to irinotecan occurred in eight out of 26 patients. 5-HT3 antag-
onists were given prophylactically to patients with severe nausea
or vomiting before the next infusion of irinotecan.
In contrast to the nonhaematologic toxicities, haematologic
toxicity was mild at any dose level (Table 3).
No consisting or late toxicity was observed in this study.
Response
The response to combined irinotecan-radiation therapy is shown in
Table 4. Of the 26 patients, three achieved a complete response, 17
had a partial response, and two had stable disease. Two patients
were not evaluable for response, including one who only received
a single intravenous infusion of irinotecan and one who died of
disease progression early in the treatment period. Overall, the
objective response rate was 76.9% (95% CI: 53.0–88.9%). No
significant differences in response were observed between the
three dose levels of irinotecan.
Survival
After a minimum follow-up period of 22 months, 16 patients have
died (13 of documented disease progression and three of other
diseases) and 10 patients remain alive at the time of analysis (five
with and five without disease progression). No patient has been
monitored for more than 36 months. The estimated 1- and 2-year
survival rates were 61.5% and 38.5%, and the median survival
time was 15.7 months for all eligible patients (Figure 2). Survival
was also compared between the three dose levels of irinotecan.
The 1-year survival rate was 50.0% at 30 mg m–2, 64.7% at 
45 mg m–2, and 40.0% at 60 mg m–2. There was no significant
difference of survival in relation to the irinotecan dose.
Table 3 Haematologic toxicity
Dose WBC Count Haemoglobin Platelet count
(mg m–2) Patients (n)( ´103 ml–1) (g dl–1)( ´ 103 ml–1)
Mean Range Mean Range Mean Range
Phase I 30 4 3.6 1.8–5.1 10.4 9.6–11.4 208  146–283
45 7 3.4 2.0–7.7 10.1 8.5–11.8 242 89–379
60 5 3.1 1.5–5.5 9.8 8.7–10.7 308 184–545
Phase II 45 10 2.6 1.6–5.9 10.1 8.7–11.4 198 118–350
Table 4 Response to treatment
Dose level of CPT-11 No. of Response Response
(mg m–2) pts CR PR NC PD NE rate (%)
30 4 1 2 1 0 0 75.0
Phase I 45 7 0 4 2 0 1 57.1
60 5 1 3 1 0 0 80.0
Phase II 45 10 1 8 0 0 1 90.0
Overall 26 3 17 4 0 2 76.9*
*95%CI 53.0–88.9%. CR: complete response; PR: partial response; NC: no change; PD: progressive disease; NE; not evaluable case
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Figure 2 Survival. The estimated 1- and 2-year survival rates were 61.5%
and 36.0%, and the median survival time was 15.7 months for 26 eligible
patients. Excluding patients with ECOG performance status of 2, the
estimated 1- and 2-year survival rates were 68.2% and 45.5%, and the
median survival time was 21.5 months1466 K Takeda et al
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The estimated 1- and 2-year survival rates were 68.2% and
45.5%, and the median survival time was 21.5 months for the
group of patients who had an ECOG performance status of 0 or 1,
and less than 5% weight loss within the last 3 months.
Pattern of failure
The sites of initial failure are shown in Table 5. The primary
tumour inside the radiation field was the site of initial failure in
eight patients (seven without and one with distant metastasis),
while distant metastasis was the cause of failure in five patients. In
five patients, including all three patients who achieved a complete
response, there is no evidence of recurrent disease.
The estimated local progression-free survival rate was 49.0% at
1 year and 39.2% at 2 years, with a median of 11.6 months. The
overall progression-free survival rate was 38.5% at 1 year and
30.8% at 2 years, with a median of 10.9 months.
DISCUSSION
Several randomized trials comparing thoracic radiotherapy alone
with radiotherapy plus chemotherapy have been reported. The first
large trial to demonstrate a significant survival benefit with multi-
modal therapy was performed by the Cancer and Leukemia Group
B (CALGB) (Dillman et al, 1990). Subsequently, the Radiation
Therapy Oncology Group (RTOG) and the Eastern Cooperative
Oncology Group (ECOG) performed a confirmatory trial (Sause et
al, 1995). Both median and long-term survival were superior in the
patients receiving multimodal treatment, confirming the results of
the CALGB study. Favourable results have also been reported
by French investigators (Le Chevalier et al, 1991). The overall
incidence of distant metastasis was reduced in the chemotherapy-
treated population, but local control was poor in both groups.
These observations indicate that the survival benefit derived from
chemotherapy comes from a reduction in the incidence of distant
metastases rather than the radiation-sensitizing effect of the agents
employed. The extremely poor local control rate is discouraging
and suggests that further efforts to improve the control of the
primary lesion are needed. The European Organization for
Research and Treatment of Cancer (EORTC) performed a random-
ized study of inoperable NSCLC that compared split course radio-
therapy alone versus the same radiotherapy plus cisplatin,
administered daily or weekly (Schaake-Koning et al, 1992). Their
findings confirmed the observation that cisplatin increases the
therapeutic ratio of radiation, with the magnitude of the synergism
depending on the administration schedule for the two agents. In
addition, survival benefit of daily combined treatment was due to
improved local control.
We initiated a first clinical trial of irinotecan combined with
concurrent radiation therapy for locally advanced NSCLC in an
attempt to increase locoregional control by employing its radio-
sensitizing effect. The present phase I/II study demonstrated that
concurrent radiation therapy can be safely delivered with
irinotecan at a dose of 45 mg m–2 over 6 weeks in patients with
locally advanced NSCLC. Oesophagitis, pneumonitis, and diar-
rhoea were the dose-limiting toxicities. Since oesophagitis and
pneumonitis were severe at the highest dose level (60 mg m–2
weekly for 6 weeks), 60 mg m–2 was concluded to be the MTD and
45 mg m–2 was the dose used in the phase II study. Although
oesophagitis and pneumonitis were generally not so severe in the
phase II study, one patient died of pneumonitis. This patient was a
71-year-old man with PS 1. His pretreatment profiles met the eligi-
bility requirements in this study. However, he had a large tumour
in the right lower lung and the radiation field was approximately
half of the hemithorax. Thus, his fatal pneumonitis could have
been related to the relatively large radiation field. Patients with
large radiation field therefore have to be excluded in this combined
therapy.
The objective response rate in the current study was 76.9%
(95% CI, 53.0–88.9%). The median survival time was 15.7 months
for all 26 patients, and the 1- and 2-year survival rates were 61.5%
and 38.5%, respectively. Although the number of subjects is small
in this study, these results compare favourably with those of other
chemoradiation trials (Dillman et al, 1990; Le Chevalier et al,
1991; Morton et al, 1991; Sause et al, 1992; Schaake-Koning,
1992; Trovo et al, 1992; Sause et al, 1995; Jeremic et al, 1996).
The selection criteria employed by CALGB were fairly restric-
tive, so only patients with low-bulk disease (i.e. supraclavicular
nodal involvement excluded), a good performance status (0 or 1),
and minimal weight loss (5% or less of body weight) were
included (Dillman et al, 1990). Thus, extrapolating the results of
these trials to all stage III patients is potentially problematic. The
RTOG and ECOG trial was done using virtually identical selection
criteria, and it confirmed the results of the CALGB study (Sause
et al, 1995).
In the present study, survival was at least as good as or better
than that in the CALGB or RTOG-ECOG studies, although our
entry criteria were less restrictive. The estimated 1- and 2-year
survival rates were 68.2% and 45.5%, and the median survival
time was 21.5 months for the group of patients excluding an
ECOG performance status of 2, and more than 5% weight loss
within the last 3 months. Compared with the reports by EORTC,
our results were encouraging in survival benefits. Weekly adminis-
tration of irinotecan combined with radiotherapy is sufficiently
encouraging to merit further evaluation of the regimen in a
randomized trial.
In conclusion, oesophagitis, pneumonitis, and diarrhoea were
the dose-limiting toxicities of weekly irinotecan combined with
thoracic irradiation. The MTD and the recommended dose were
60 mg m–2 wk–1 and 45 mg m–2 wk–1, respectively. This combined
Table 5 Pattern of failure
Site of initial failure Patients (n)%
Inside radiation field 8 40
Primary tumour site 8 40
Other site 0 0
Outside radiation field 5 25
Brain 2 10
Peritoneal lymph nodes 2 10
Contralateral supraclavicular lymph nodes 1 5
Response continued 5 25
Unknown* 2 10
*Patients died without disease progression, including one who had treatment-
related death, one who died of other diseaseIrinotecan and concurrent radiation for NSCLC 1467
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therapy for locally advanced NSCLC appears to be promising and
tolerable.
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